281 related articles for article (PubMed ID: 30578762)
1. Prognostic significance of circulating tumor cells (CTCs) in Egyptian non-metastatic colorectal cancer patients: A comparative study for four different techniques of detection (Flowcytometry, CellSearch, Quantitative Real-time PCR and Cytomorphology).
Bahnassy AA; Salem SE; Mohanad M; Abulezz NZ; Abdellateif MS; Hussein M; Zekri CAN; Zekri AN; Allahloubi NMA
Exp Mol Pathol; 2019 Feb; 106():90-101. PubMed ID: 30578762
[TBL] [Abstract][Full Text] [Related]
2. Colorectal Cancer CTCs Detection Using Two FCM Protocol Approaches.
Mourtzikou A; Stamouli M; Karakitsos P; Athanasas G
Clin Lab; 2019 Jun; 65(6):. PubMed ID: 31232030
[TBL] [Abstract][Full Text] [Related]
3. Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma.
Yu XM; Wu YC; Liu X; Huang XC; Hou XX; Wang JL; Cheng XL; Mao WM; Ling ZQ
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827952
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients.
Shimada R; Iinuma H; Akahane T; Horiuchi A; Watanabe T
Oncol Rep; 2012 Apr; 27(4):947-53. PubMed ID: 22267181
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.
Bahnassy AA; Zekri AR; El-Bastawisy A; Fawzy A; Shetta M; Hussein N; Omran D; Ahmed AA; El-Labbody SS
World J Gastroenterol; 2014 Dec; 20(48):18240-8. PubMed ID: 25561791
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer.
Messaritakis I; Sfakianaki M; Papadaki C; Koulouridi A; Vardakis N; Koinis F; Hatzidaki D; Georgoulia N; Kladi A; Kotsakis A; Souglakos J; Georgoulias V
Cancer Chemother Pharmacol; 2018 Nov; 82(5):767-775. PubMed ID: 30094617
[TBL] [Abstract][Full Text] [Related]
7. mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients.
Mostert B; Sieuwerts AM; Bolt-de Vries J; Kraan J; Lalmahomed Z; van Galen A; van der Spoel P; de Weerd V; Ramírez-Moreno R; Smid M; Verhoef C; IJzermans JN; Gratama JW; Sleijfer S; Foekens JA; Martens JW
Mol Oncol; 2015 Apr; 9(4):920-32. PubMed ID: 25655581
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of CD133
Fang C; Fan C; Wang C; Huang Q; Meng W; Yu Y; Yang L; Hu J; Li Y; Mo X; Zhou Z
Cancer Med; 2017 Dec; 6(12):2850-2857. PubMed ID: 29105339
[TBL] [Abstract][Full Text] [Related]
9. The role of circulating tumor cells in metastatic breast cancer: prognostic and predictive value.
Bahnassy AA; Saber MM; Mahmoud MG; Abdellateif MS; Abd El-Mooti Samra M; Abd El-Fatah RM; Zekri AN; Salem SE
Mol Biol Rep; 2018 Dec; 45(6):2025-2035. PubMed ID: 30229477
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
[TBL] [Abstract][Full Text] [Related]
11. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables.
Sastre J; Maestro ML; Puente J; Veganzones S; Alfonso R; Rafael S; García-Saenz JA; Vidaurreta M; Martín M; Arroyo M; Sanz-Casla MT; Díaz-Rubio E
Ann Oncol; 2008 May; 19(5):935-8. PubMed ID: 18212090
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.
Gasch C; Bauernhofer T; Pichler M; Langer-Freitag S; Reeh M; Seifert AM; Mauermann O; Izbicki JR; Pantel K; Riethdorf S
Clin Chem; 2013 Jan; 59(1):252-60. PubMed ID: 23136247
[TBL] [Abstract][Full Text] [Related]
16. Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry.
Lu Y; Liang H; Yu T; Xie J; Chen S; Dong H; Sinko PJ; Lian S; Xu J; Wang J; Yu S; Shao J; Yuan B; Wang L; Jia L
Cancer; 2015 Sep; 121(17):3036-45. PubMed ID: 25945459
[TBL] [Abstract][Full Text] [Related]
17. Development of a molecular multimarker assay for the analysis of circulating tumor cells in adenocarcinoma patients.
de Albuquerque A; Kubisch I; Ernst D; Breier G; Stamminger G; Fersis N; Stölzel U; Boese-Landgraf J; Eichler A; Kaul S
Clin Lab; 2012; 58(5-6):373-84. PubMed ID: 22783565
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
[TBL] [Abstract][Full Text] [Related]
19. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
20. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse M; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
J Clin Oncol; 2008 Jul; 26(19):3213-21. PubMed ID: 18591556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
